Skba Capital Management LLC Has $303,000 Holdings in Johnson & Johnson (JNJ)

Skba Capital Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 19.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,500 shares of the company’s stock after selling 600 shares during the period. Skba Capital Management LLC’s holdings in Johnson & Johnson were worth $303,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock worth $136,289,000 after acquiring an additional 38,285 shares during the period. Sather Financial Group Inc lifted its holdings in shares of Johnson & Johnson by 3.7% during the 2nd quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock worth $1,341,000 after acquiring an additional 399 shares during the period. Concentric Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock worth $3,229,000 after acquiring an additional 813 shares during the period. Narwhal Capital Management lifted its holdings in shares of Johnson & Johnson by 2.5% during the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock worth $4,965,000 after acquiring an additional 1,010 shares during the period. Finally, Cardinal Capital Management lifted its holdings in shares of Johnson & Johnson by 10.6% during the 2nd quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock worth $12,342,000 after acquiring an additional 9,767 shares during the period. Hedge funds and other institutional investors own 66.51% of the company’s stock.

In other Johnson & Johnson news, VP Peter Fasolo sold 166,695 shares of the firm’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $146.41, for a total value of $24,405,814.95. Following the transaction, the vice president now directly owns 155,540 shares of the company’s stock, valued at $22,772,611.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alex Gorsky sold 264,465 shares of the firm’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $145.96, for a total transaction of $38,601,311.40. Following the completion of the transaction, the chief executive officer now directly owns 481,254 shares in the company, valued at $70,243,833.84. The disclosure for this sale can be found here. Insiders sold 510,544 shares of company stock worth $74,414,877 over the last ninety days. Insiders own 0.22% of the company’s stock.



A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 price target for the company in a report on Wednesday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Raymond James increased their price objective on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Finally, Credit Suisse Group set a $149.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $143.90.

JNJ opened at $145.91 on Friday. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. The firm has a market cap of $391.78 billion, a PE ratio of 19.99, a PEG ratio of 2.28 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://dakotafinancialnews.com/2018/12/07/skba-capital-management-llc-has-303000-holdings-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply